87 results about "Pancreatic disease" patented technology

The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as pancreatic disease, and using the profile in assessing the condition of a patient.

The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAST) and antibodies binds to PCAST. The present invention provides that PCAST is used as targets for screening agents that modulates the PCAST activities. Further the present invention provides methods for treating diseases associated with pancreas.

Methods of ex-vivo expansion of endodermally-derived and non-endodermally-derived progenitor and stem cells, expanded populations of renewable progenitor and stem cells and to their uses in therapeutic applications such as the production of endocrine hormones and the prevention and treatment of liver and pancreatic disease.

Methods and compositions for at least determining whether a human subject has a pancreatic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a pancreatic glycoprotein (GP2) analyte to determine whether the subject at least has the pancreatic disease. Also provided are kits, systems, and devices for practicing the subject methods.

Pharmaceutical composition for regulation of pancreatic juice secretion characterized by comprising a lisophosphatidic acid (LPA) receptor modulator. Since an LPA receptor modulator has an effect of regulating the secretion of pancreatic juice, a compound acting on this receptor is useful in treating diseases in association with disorders in pancreatic juice secretion. For example, an LPA receptor agonist is useful in treating and / or preventing pancreatic diseases and obesity, while an LPA receptor antagonist is useful in treating and / or preventing maldigestion, constipation, diarrhea and cibophobia.

The invention belongs to the technical field of medical apparatus and instruments, and in particular relates to a multi-purpose nasal biliary drainage tube. The multi-purpose nasal biliary drainage tube comprises a drainage tube section I, a drainage tube section II, a drainage tube section III, a drainage tube section IV, a drainage tube section V and a drainage tube section VI, wherein the drainage tube section I is of straight line type, the drainage tube section II is spiral, and a channel I in the drainage tube section II communicates with the drainage tube section I; the center of the drainage tube section III is bent, the formed angle alpha is 30-45 degrees, a channel III in the drainage tube section III communicates with the channel I, and a channel IV in the drainage tube sectionIII communicates with a channel II; the center of the drainage tube section IV is bent, the formed angle beta is 60-90 degrees, and the drainage tube section IV communicates with the channel III; thecenter of the drainage tube section V is bent, the formed angle gamma is 60-120 degrees, and a channel V of the drainage tube section V communicates with the channel III; the drainage tube section VIis of straight line type, a channel VII in the drainage tube section VI communicates with the channel V, and a channel VIII in the drainage tube section VI communicates with the channel VI. The multi-purpose nasal biliary drainage tube can be widely popularized and applied in the fields including endoscope treatment for the diseases including hepatobiliary and pancreatic diseases.

Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease.

The subject invention comprises culture methods for transdifferentiation of non-pancreatic stem cells to the pancreatic differentiation pathway. It also concerns the endocrine hormones that can be produced by such cultures, and the use of the transdifferentiated cells in the treatment of pancreatic diseases.

A pancreatic disease is tested for with high sensitivity even with simple equipment and a simple procedure. Provided is a method of detecting pancreatic disease including detecting a concentration of S100P in at least one of a pancreatic juice and a body fluid containing pancreatic juice collected from a test subject by immunochromatography. Additionally provided is a pancreas testing kit including an immunochromatography device that holds an anti-S100P antibody and a collection vessel that retains a protease inhibitor that inhibits an activity of a protease contained in the pancreatic juice.

Methods and related kits for differentiating pancreatic cancer from a benign pancreatic disease. The method includes assaying a patient biological sample for a total level of CA 19-9 antigen and for a glycan level in specific mucin(s), and comparing the total level of CA 19-9 antigen and the glycan level in the specific mucin(s) to statistically validated thresholds, wherein a different level of total CA 19-9 antigen in the patient biological sample as compared to a statistically validated threshold and a different level of glycan level in the specific mucin(s) as compared to statistically validated thresholds indicate pancreatic cancer in the patient rather than a benign pancreatic disease.

The invention discloses a medicine preparation of trypsin enteric coated pellets. The preparation consists of active trypsin powder, a polyol medical excipient, a disintegrant and an enteric coating material containing an anti-adhesion agent. The pellet medicine preparation of the invention is prepared by an extruding-rolling technique. The preparation is used for treating dyspepsia, gastricism caused by pancreatic diseases and dyspepsia of diabetic patients, etc.

The present invention provides a method for diagnosing and detecting diseases associated with pancreas. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in pancreatic diseases (PCAST) and antibodies binds to PCAST. The present invention provides that PCAST is used as targets for screening agents that modulates the PCAST activities. Further the present invention provides methods for treating diseases associated with pancreas.

Dietary supplements and food comprising a mixture of glucomannan, xanthan gum and alginate. The foods and supplements are used for delaying the onset of, slowing the progression of, and / or ameliorating at least one symptom of, metabolic syndrome, type I diabetes, type II diabetes, pancreatic disease or hyperlipidemia. The mixture of glucomannan, xanthan gum and alginate is analysed using standard methods of carbohydrate analysis involving acid hydrolysis of the polysaccharides followed by chromatographic separation.

The invention discloses a method for synthesizing 13C-labeled cholesterol carboxylic ester. The 13C-labeled cholesterol carboxylic ester is synthesized by using 13C-labeled carboxylic acid and cholesterol as raw materials in the presence of condensing agent. The yield of the synthesized 13C-labeled cholesterol carboxylic ester is 80 to 90 percent, the 13C abundance is 99 atom percent, the chemical purity is 99 percent, and the 13C-labeled cholesterol carboxylic ester fully meets the requirement of medicinal reagent. The 13C-labeled cholesterol carboxylic ester is a medicinal 13C respiration reagent, and can be used for diagnosis of pancreatic disease and the like.

Methods and compositions for diagnosing, detecting and treating a pancreatic disease associated with differential expression of E-cadherin in comparison to healthy cells. Also provided are antagonists or agonists of E-cadherin, and methods for screening agents that modulate the E-cadherin level or activity in vivo or in vitro.

The invention discloses a total RNA extracting method of pancreatic tissue of acute pancreatic disease animal, which comprises the following steps: preparing lavage liquid; breeding film after degerming for 2h in the 95% O2 and 5% CO2; narcotizing the ill animal; plugging pipe into main pancreatic duct from the opening of duodenum; injecting fitful quantity of lavage liquid; cutting the pancreatic tissue; pruning in the soy parenzyme inhibitor under 4 deg. c; washing; placing in the TRlzol cracking liquid to homogenize at 4 deg. c; extracting the total RNA of pancreatic tissue according to the instruction of TRlzol cracking liquid agent box; detecting the density and the rate of OD260 and OD280 through spectrophotometric method; estimating the density; identifying the completeness integrity through 1% agarose gel electrophoresis.

The invention discloses a Miao medicine for treating pancreatic diseases and relates to a Miao medicine prepared by taking Chinese herbal medicines as raw materials. A medicinal formula of the Miao medicine comprises the following ingredients: 4-6g of Rhubarb, 4-6g of Rhizoma Ligustici Wallichii, 6-12g of Pinellia, 6-12g of Carpesium Abrotanoides and 6-12g of Cumin. The pancreatic diseases comprise pancreatitis, pancreas necrosis and pancreatic cancer. A preparation method for the Miao medicine comprises the following steps of: preparing medicines according to a formula, decocting the medicines with clear water, concentrating, filtering and removing residues to obtain decoction; or and grinding raw herbal materials into powder after mixing to obtain pulvis; or grinding the raw herbal materials after evenly mixing, and putting the powder into capsules to prepare capsules. The Miao medicine has the characteristics of being marvelously quick in curative effect as the Miao medicine can take effect after patients take the Miao medicine for 1 hour and high in cure rate, relieving the pain of patients who cannot take food to save lives of the patients and eliminate death threats, being wide in material sources and convenient in preparation, and being capable of being decocted in water for oral dose, ground into powder for swallowing, put into capsules for taking, or prepared into tincture and injection for use so as to be low in preparation cost and good in effect. The Miao medicine is applicable to the treatment of the patients with the pancreatic diseases.

The invention belongs to the technical field of medical instruments and particularly relates to a release and retrieval unit of a fully-covered self-expanding metal stent for endoscopic retrograde cholangiopancreatography, comprising a core tube, an inner sleeve, an outer sleeve, and a loop; the tail end of the core tube is a dual-cavity catheter; cavity I of the core tube passes through a loop metal rod, cavity II is communicated with a single-cavity catheter at the head of the core tube; the connection between the single-cavity catheter of the core tube and the dual-cavity catheter is provided with a U-shaped groove; the head of the core tube is connected with a conical cap having a hole; the core tube is sleeved with the inner sleeve; the inner sleeve is sleeved with the outer sleeve. The release and retrieval unit is suitable for wide popularization and application in the fields, such as endoscopic fully-covered self-expanding metal stenting for biliary-pancreatic diseases.

The present invention relates to miRNA biomarkers for use in the diagnosis of pancreatic diseases, in particular pancreatic cancers and pre-cancerous diseases, such as pancreatic ductal adenocarcinoma (PDAC), in particular the early detection of PDAC. The miRNA biomarkers are miR-143, miR-223, miR-204, miR-30e, miR-26a, miR-30a, miR-30b and miR-106b. They may be combined with protein biomarkers. The present invention also provides methods of diagnosis and treatment of PDAC and related diseases, and kits for the early detection of PDAC based on the expression levels of the biomarkers in biological samples, in particular urine samples.

Methods and compositions for diagnosing, detecting a pancreatic disease associated with differential expression of PCATs (e.g., CD49b, CD51, CD71 and E-Cadherin) in comparison to healthy cells.

Intrabiliary hydrodynamic injection of nucleic acid for in vivo gene therapy for treatment of liver or pancreas disease and other disorders.

The invention discloses a construction method of an SD (Sprague Dawley) rat pancreas duct epithelial cell model. The construction method adopts a rat and is characterized by further comprising steps as follows: animal selection and anesthesia, surgical separation of a main pancreatic duct of the rat, chemical digestion of the main pancreatic duct and cell type identification. According to the construction method, the main pancreatic duct is directly separated under the naked eyes according to a pancreatic anatomical structure of the SD rat, the separation recovery rate of epithelial cells of the pancreatic duct is higher, the obtained epithelial cells of the pancreatic duct are less irritated, and stable passage can be realized. The method is simple and convenient, the success rate is high, and the novel cell model with rich and reliable sources is provided for research of diseases of pancreas.

Methods and compositions for diagnosing, detecting and treating a pancreatic disease associated with differential expression of CD71 in comparison to healthy cells. Also provided are antagonists or agonists of CD71, and methods for screening agents that modulate the CD71 level or activity in vivo or in vitro.

Provided are a method for exclusively selecting a duodenal fluid sample having a high possibility of containing pancreatic fluid and favorable sample suitability for subjecting to detection of a pancreatic disease marker by evaluating the quality of the sample prior to detecting the pancreatic disease marker, and a method for detecting a pancreatic disease marker using a duodenal fluid sample selected according to that method. Namely, a method is provided for selecting a duodenal fluid sample for detecting a pancreatic disease marker, comprising: (a1) a step of comparing the color depth of a duodenal fluid sample with a prescribed standard color, and (b1) a step of determining that a duodenal fluid sample is subjected to a test for a pancreatic disease marker if the color depth thereof is equal to or higher than the standard color, but that the duodenal fluid sample is not subjected to a test for a pancreatic disease marker if the color depth thereof is lower than the standard color.

The present application describes a binding epitope to Helicobacter pylori, namely substances comprising the oligosaccharide sequence -Gal(Nac)r2$g(b)4Glc(A)q2(Nac)r3-, and the use thereof in pharmaceutical and nutritional compositions for the treatment of conditions due to the presence of Helicobacter pylori in a subject, e.g. gastritis, gastric ulcers, gastric adenocarcinoma, liver disease, pancreatic disease, skin disease, heart disease, autoimmune diseases and sudden infant death syndrome. The invention is also directed to the use of the receptor for diagnostics of Helicobacter pylori, to a method of producing chondroitin oligosaccharides from chondroitin sulphates, and a method for production of amidated glucuronic acid comprising oligosaccharides and monosaccharides from glucuronic acid comprising polysaccharides.

Methods and compositions for diagnosing, detecting and treating a pancreatic disease associated with differential expression of CD51 in comparison to healthy cells. Also provided are antagonists or agonists of CD51, and methods for screening agents that modulate the CD51 level or activity in vivo or in vitro.

Methods and compositions for diagnosing, detecting and treating a pancreatic disease associated with differential expression of E-cadherin in comparison to healthy cells. Also provided are antagonists or agonists of E-cadherin, and methods for screening agents that modulate the E-cadherin level or activity in vivo or in vitro.

The present invention relates to the structural proteins of the causative agent of Pancreatic Disease in fish, nucleotide sequences encoding said proteins, vaccines comprising said proteins or nucleotide sequences and diagnostic kits comprising said proteins or nucleotide sequences.

The invention discloses a preparation method and application of pancreatic progenitor cells, and relates to the technical field of stem cell differentiation regulation, and the preparation method comprises the following steps: inducing posterior segment cells of a posterior intestine to differentiate into pancreatic progenitor cells by adopting a differentiation inducer; the differentiation inducer comprising a casein kinase 1 inhibitor. The inventor finds that the casein kinase 1 inhibitor plays an important role in the differentiation process of pancreatic progenitor cells, and can promote the acquisition of the pancreatic progenitor cells and / or pancreatic beta cells in a serum-free induction environment, thereby providing a new way for effectively acquiring the pancreatic progenitor cells and the pancreatic beta cells. Meanwhile, a foundation is laid for treating diabetes mellitus or other pancreatic diseases by a pancreatic cell replacement therapy.